Evommune, Inc. EVMN
6.54 USD +0.50 (+8.28%)
Nov 5, 2026, 12:24 PM EST
6.50 Day range 7.15
5.10 52-week range 31.57
- YTD
- -61.80%
- 1 year
- -67.67%
- Market cap
- 236.99M
- EPS (ttm)
- -3.75
- YTD return
- -61.80%
- 1-year return
- -67.67%
- Volume
- 659.43K
- Avg volume
- 774.30K
- Open
- 6.65
- Previous close
- 6.04
- Day's range
- 6.50 – 7.15
- 52-week range
- 5.10 – 31.57
5D -0.15 (-2.36%)
Financials — quick view
EVMN Revenue — quarterly 0
EVMN Net income — quarterly -32.25M
EVMN EPS — quarterly -0.89
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET 
Evommune Announces $30 Million Private Placement 
Evommune Receives Exclusive License From Hinova Pharmaceuticals To Develop, Manufacture, Commercialize EVO570 Outside China; Hinova To Get $30M Upfront Payment 
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8 
Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027 
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress 
Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
Your note
Sign in to keep a note on EVMN — it syncs with the Stock Master app.